GlassScriptPhysician profile
Sandra L Ellis
NPI 1861419491
$3,266.55
in general payments reported to CMS, 2019-2025
25 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $89.55 · 2021: $903 · 2022: $700 · 2023: $662 · 2024: $363 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,367.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $919.61 | 2019-2024 | Wegovy, Ozempic |
| Abbott Laboratories | $429.42 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $365.80 | 2020-2023 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $258.39 | 2019-2022 | |
| Exact Sciences Corporation | $219.33 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $190.69 | 2019-2025 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $190.17 | 2021-2023 | |
| Pfizer INC. | $107.63 | 2021-2023 | |
| Abbvie INC. | $103.91 | 2021-2022 | |
| Corcept Therapeutics | $89.72 | 2021-2023 | Korlym |
| Dynavax Technologies Corporation | $69.74 | 2021-2023 | Heplisav-B |
| Lucid Diagnostics INC. | $45.26 | 2022-2023 | |
| Daiichi Sankyo INC. | $42.78 | 2021 | |
| Ibsa Pharma INC. | $30.11 | 2019-2023 | Tirosint, Licart |
| Biohaven Pharmaceuticals, INC. | $24.55 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $24.35 | 2021 | |
| Astellas Pharma US INC | $22.55 | 2023 | Veozah |
| Amag Pharmaceuticals, INC. | $20.39 | 2019 | |
| Hologic Sales and Service, LLC | $20.21 | 2022 | |
| Eisai INC. | $20.20 | 2021 | |
| Gilead Sciences, INC. | $16.20 | 2021 | |
| Lilly USA, LLC | $15.32 | 2019 | |
| Glaxosmithkline, LLC. | $14.22 | 2022 | |
| Medtronic, INC. | $14.19 | 2021 | |
| Cranial Technologies, INC | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.